Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells

Activating mutations of epidermal growth factor receptor (EGFR) contributes to the progression of non-small cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitor (TKI)-targeted therapy has become the standard treatment for NSCLC patients with EGFR-mutations. However, acquired resistance to these...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun, Liu, Xi, Huang, Yuanfeng, Li, Pan, Yang, Minqiang, Zeng, Shanshan, Chen, Danyang, Wang, Qian, Liu, Hao, Luo, Kai, Deng, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986855/
https://www.ncbi.nlm.nih.gov/pubmed/35387964
http://dx.doi.org/10.1038/s41420-022-00966-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986855/
https://www.ncbi.nlm.nih.gov/pubmed/35387964
http://dx.doi.org/10.1038/s41420-022-00966-x

Ejemplares similares